GlassScriptPhysician profile
Lynette Weitman Nicholson
NPI 1538378823
$48,995.54
in general payments reported to CMS, 2019-2025
36 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,087 · 2022: $6,612 · 2023: $12K · 2024: $4,147 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $11K · Consulting Fee: $7,020 · Travel and Lodging: $1,047 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,690.00 |
| Food and Beverage | $11,484.65 |
| Consulting Fee | $7,020.00 |
| Travel and Lodging | $1,046.77 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20,343.43 | 2021-2025 | Taltz |
| Ucb, INC. | $14,101.77 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $2,608.89 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $2,438.16 | 2021-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $2,356.25 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $1,453.48 | 2021-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $943.18 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $680.77 | 2022-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $666.59 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $418.37 | 2021-2025 | Orencia |
| Pfizer INC. | $402.81 | 2021-2025 | |
| Glaxosmithkline, LLC. | $363.75 | 2021-2025 | Benlysta |
| Radius Health, INC. | $309.42 | 2021-2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $245.24 | 2024-2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $177.11 | 2021-2025 | Actemra, Gazyva, Ocrevus Zunovo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $158.45 | 2021-2023 | Krystexxa |
| Cumberland Pharmaceuticals, INC. | $140.69 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.89 | 2022-2025 | Ofev, Cyltezo |
| Alvogen INC | $121.70 | 2022-2025 | Teriparatide |
| Pacira Therapeutics, INC. | $110.59 | 2021 | |
| Invivyd INC | $98.29 | 2025 | Pemgarda |
| Genzyme Corporation | $92.50 | 2025 | |
| Organon LLC | $79.75 | 2021-2024 | |
| Kyowa Kirin, INC. | $71.17 | 2024-2025 | Crysvita |
| Sobi, INC | $64.84 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $55.36 | 2022-2023 | Strensiq |
| Bioventus LLC | $51.04 | 2022-2025 | Xcell |
| Fresenius Kabi USA, LLC | $49.90 | 2024-2025 | |
| Octapharma USA, INC. | $47.72 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $38.65 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $38.20 | 2024 | Arcalyst |
| Sandoz INC. | $34.50 | 2024-2025 | Hyrimoz |
| Actelion Pharmaceuticals US, INC. | $33.71 | 2025 | Opsumit, Uptravi |
| Ascend Therapeutics US, LLC | $32.00 | 2022 | |
| Depuy Synthes Sales INC. | $20.04 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynette Weitman Nicholson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.